What is Machavert?
Machavert Pharmaceuticals is a preclinical biopharmaceutical firm dedicated to pioneering novel therapeutics for cancer and autoimmune diseases. The company's core strategy revolves around precision medicine, with a specific emphasis on targeting KRAS mutant cancers and leveraging bioactive phospholipids for immuno-oncology applications. Machavert's proprietary drug delivery platform is engineered for the selective targeting of solid tumors, aiming to enhance therapeutic efficacy while minimizing off-target effects on healthy tissues. This approach is designed to significantly improve patient outcomes for those facing challenging oncological and autoimmune conditions.
How much funding has Machavert raised?
Machavert has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Machavert?
With its recent major strategic investment, Machavert is poised to accelerate its preclinical development pipeline and advance its innovative therapeutic candidates toward clinical trials. The substantial capital infusion, indicated by $150K, suggests a late-stage funding environment, enabling the company to scale its operations, expand its research and development capabilities, and potentially forge strategic partnerships. This financing is critical for Machavert to further validate its precision medicine approach and its unique drug delivery system, paving the way for future commercialization and market entry in the competitive biopharmaceutical landscape.
See full Machavert company page
